Not Signed In - Positive Results From Combination Trials Build On VELCADE(R) (Bortezomib) For Injection Proven Single-Agent Strength In Relapsed Multiple Myeloma
Tue, 12 Dec 2006 08:00 AM EST
... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported presentation of results from several clinical trials of VELCADE(R) (bortezomib) for Injection combination therapies for treatment of relapsed multiple myeloma (MM). [click link for full article] ...
Related Topics
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Bortezomib
- Agent Orange
- Chemical Agents
- Thalidomide
- Multiple myeloma cancer
- Plasma Cell Neoplasm/Multiple Myeloma
- Multiple Myeloma/Other Plasma Cell Neoplasms
- Multiple Myeloma/Plasma Cell Neoplasm
- Travel Destinations
- Multiple Chemical Sensitivity
- Aluminum Hydroxide, Magnesium Carbonate Oral Suspension
- Combination Vaccines
- ACT
- Twins, Triplets, Multiple Births
- Interferon Beta-1a Injection (Rebif
- Multiple System Atrophy
- Interferon Beta-1a Injection (Avonex
email this page
print this page
bookmark this page
feedback on this page
